Cargando…
Effect of α-Lipoic Acid on Platelet Reactivity in Type 1 Diabetic Patients
OBJECTIVE: Type 1 diabetes is associated with increased platelet reactivity. We investigated whether α-lipoic acid (ALA) has any effect on platelet reactivity in these patients. RESEARCH DESIGN AND METHODS: We randomly assigned 51 type 1 diabetic patients to ALA (600 mg once daily) or placebo for 5...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Diabetes Association
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3263886/ https://www.ncbi.nlm.nih.gov/pubmed/22228743 http://dx.doi.org/10.2337/dc11-1255 |
_version_ | 1782221943718543360 |
---|---|
author | Mollo, Roberto Zaccardi, Francesco Scalone, Giancarla Scavone, Giuseppe Rizzo, Paola Navarese, Eliano Pio Manto, Andrea Pitocco, Dario Lanza, Gaetano Antonio Ghirlanda, Giovanni Crea, Filippo |
author_facet | Mollo, Roberto Zaccardi, Francesco Scalone, Giancarla Scavone, Giuseppe Rizzo, Paola Navarese, Eliano Pio Manto, Andrea Pitocco, Dario Lanza, Gaetano Antonio Ghirlanda, Giovanni Crea, Filippo |
author_sort | Mollo, Roberto |
collection | PubMed |
description | OBJECTIVE: Type 1 diabetes is associated with increased platelet reactivity. We investigated whether α-lipoic acid (ALA) has any effect on platelet reactivity in these patients. RESEARCH DESIGN AND METHODS: We randomly assigned 51 type 1 diabetic patients to ALA (600 mg once daily) or placebo for 5 weeks. Platelet reactivity was evaluated by the PFA-100 method and by measuring CD41 and CD62 platelet expression. C-reactive protein (CRP) and 8-iso-prostaglandin F2α serum levels also were measured. RESULTS: Baseline variables were similar in the two groups. After treatment, closure time was longer (P = 0.006) and CD62P platelet expression was lower, both before (P = 0.002) and after (P = 0.009) ADP stimulation in the ALA group compared with the placebo group. CRP and 8-iso-prostaglandin F2α levels showed no differences between the two groups. CONCLUSIONS: Our data show that ALA reduces measures of platelet reactivity ex vivo in type 1 diabetic patients, independently of antioxidant or anti-inflammatory effects. |
format | Online Article Text |
id | pubmed-3263886 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2012 |
publisher | American Diabetes Association |
record_format | MEDLINE/PubMed |
spelling | pubmed-32638862013-02-01 Effect of α-Lipoic Acid on Platelet Reactivity in Type 1 Diabetic Patients Mollo, Roberto Zaccardi, Francesco Scalone, Giancarla Scavone, Giuseppe Rizzo, Paola Navarese, Eliano Pio Manto, Andrea Pitocco, Dario Lanza, Gaetano Antonio Ghirlanda, Giovanni Crea, Filippo Diabetes Care Original Research OBJECTIVE: Type 1 diabetes is associated with increased platelet reactivity. We investigated whether α-lipoic acid (ALA) has any effect on platelet reactivity in these patients. RESEARCH DESIGN AND METHODS: We randomly assigned 51 type 1 diabetic patients to ALA (600 mg once daily) or placebo for 5 weeks. Platelet reactivity was evaluated by the PFA-100 method and by measuring CD41 and CD62 platelet expression. C-reactive protein (CRP) and 8-iso-prostaglandin F2α serum levels also were measured. RESULTS: Baseline variables were similar in the two groups. After treatment, closure time was longer (P = 0.006) and CD62P platelet expression was lower, both before (P = 0.002) and after (P = 0.009) ADP stimulation in the ALA group compared with the placebo group. CRP and 8-iso-prostaglandin F2α levels showed no differences between the two groups. CONCLUSIONS: Our data show that ALA reduces measures of platelet reactivity ex vivo in type 1 diabetic patients, independently of antioxidant or anti-inflammatory effects. American Diabetes Association 2012-02 2012-01-16 /pmc/articles/PMC3263886/ /pubmed/22228743 http://dx.doi.org/10.2337/dc11-1255 Text en © 2012 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See http://creativecommons.org/licenses/by-nc-nd/3.0/ for details. |
spellingShingle | Original Research Mollo, Roberto Zaccardi, Francesco Scalone, Giancarla Scavone, Giuseppe Rizzo, Paola Navarese, Eliano Pio Manto, Andrea Pitocco, Dario Lanza, Gaetano Antonio Ghirlanda, Giovanni Crea, Filippo Effect of α-Lipoic Acid on Platelet Reactivity in Type 1 Diabetic Patients |
title | Effect of α-Lipoic Acid on Platelet Reactivity in Type 1 Diabetic Patients |
title_full | Effect of α-Lipoic Acid on Platelet Reactivity in Type 1 Diabetic Patients |
title_fullStr | Effect of α-Lipoic Acid on Platelet Reactivity in Type 1 Diabetic Patients |
title_full_unstemmed | Effect of α-Lipoic Acid on Platelet Reactivity in Type 1 Diabetic Patients |
title_short | Effect of α-Lipoic Acid on Platelet Reactivity in Type 1 Diabetic Patients |
title_sort | effect of α-lipoic acid on platelet reactivity in type 1 diabetic patients |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3263886/ https://www.ncbi.nlm.nih.gov/pubmed/22228743 http://dx.doi.org/10.2337/dc11-1255 |
work_keys_str_mv | AT molloroberto effectofalipoicacidonplateletreactivityintype1diabeticpatients AT zaccardifrancesco effectofalipoicacidonplateletreactivityintype1diabeticpatients AT scalonegiancarla effectofalipoicacidonplateletreactivityintype1diabeticpatients AT scavonegiuseppe effectofalipoicacidonplateletreactivityintype1diabeticpatients AT rizzopaola effectofalipoicacidonplateletreactivityintype1diabeticpatients AT navareseelianopio effectofalipoicacidonplateletreactivityintype1diabeticpatients AT mantoandrea effectofalipoicacidonplateletreactivityintype1diabeticpatients AT pitoccodario effectofalipoicacidonplateletreactivityintype1diabeticpatients AT lanzagaetanoantonio effectofalipoicacidonplateletreactivityintype1diabeticpatients AT ghirlandagiovanni effectofalipoicacidonplateletreactivityintype1diabeticpatients AT creafilippo effectofalipoicacidonplateletreactivityintype1diabeticpatients |